

COVID-19

Pharmacy Assessment Protocol

ELIGIBILITY FOR SERVICE

The pharmacy will refer patients with the any of the following symptoms/conditions for further medical evaluation:

- Patients that are pregnant
- Immunocompromised
- Any condition requiring supplemental oxygen therapy
- Patients <18 and >64 years of ages
- Temperature >103° F
- Respiratory rate of >30 breaths per minute
- Oxygen saturation <94%
- Pulse > 125 beats per minute

TESTING CRITERIA

Consider testing anyone presenting within 5 days of symptom onset during times of COVID-19 activity when the result will influence clinical management and outbreak response:

Chills	Cough	Headache	Nasal congestion	Vomiting	Sore throat	Muscle pain
Fever	Shortness of breath	Rhinorrhea	Fatigue	Diarrhea	Nonproductive cough	

PRESCRIBING

Upon a positive test result, those at increased risk for progression to severed disease should be considered for treatment.

Example of increased but not high-risk factors for progression

Example health condition

- Age 65-74 years
- ASCVD
- Asthma
- Cardiomyopathy
- Cerebral Vascular Disease
- Chronic liver diseases
- Chronic lung diseases
- Cirrhosis
- Dementia
- Diabetes Mellitus
- Disabilities including Down Syndrome
- End stage renal disease
- Heart failure
- HIV with CD4 > 200
- Inflammatory bowel disease
- Mental health conditions
- Obesity
- Parkinson's Disease
- Physical inactivity
- Pregnancy (current or recent)
- Smoking history
- Solid tumor (> 12 months prior)
- Tuberculosis

Example therapeutics¹

- Anti-IL-6
- Anti-IL-12 and 23
- Corticosteroids 10-20 mg for ≥4 weeks

Note: ¹ Example therapeutics that are less likely to predispose to substantial immunosuppression

The pharmacist will identify any precautions or contraindications to therapy prior to prescribing, and if deemed appropriate, prescribe the most appropriate treatment.

Treatment		
Drug	Dose	Duration
nirmatrelvir with ritonavir	300 mg nirmatrelvir (two 150 mg tablets) with 100 mg ritonavir (one 100 mg tablet), with all 3 tablets taken together twice daily	5 Days
Dose reduction for moderate renal impairment (eGFR $\geq$30 to <60 mL/min):		
Drug	Dose	Duration
nirmatrelvir with ritonavir	150 mg nirmatrelvir (one 150 mg tablet) with 100 mg ritonavir (one 100 mg tablet), taken together twice daily	5 Days

FOLLOW-UP

The patient should be instructed to contact the pharmacy if symptoms do not improve within 48 hours or if symptoms worsen, so the pharmacist can refer the patient for further medical evaluation. If a prescription is provided, and a primary care provider is identified, the pharmacy will notify the provider of record within three business days following the patient encounter.

IDSA guidelines on the treatment and management of patients with COVID-19. October 14, 2025.